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Pneumococcal vaccination and
childhood pneumonia in South Africa
Kim Mulholland,1,2 Cattram Nguyen3
For the past 30 years the dominant role of
acute respiratory infections, especially
pneumonia, as a cause of illness and death
in children in the developing world has
been appreciated. The strategy employed
throughout the developing world to
address the problem was based on the
early detection and treatment of likely
pneumonia cases at the community level
by primary healthcare workers using a
strategy developed in Papua New Guinea
in the 1970s.1 The strategy relied on two
physical signs—fast breathing (to identify
possible pneumonia cases in need of anti-
biotics) and lower chest wall indrawing
(to identify more severe cases in need of
admission). Originally a programme,
solely for the management of acute
respiratory infection cases, this was inte-
grated, in 1991, into a broader case man-
agement strategy for young children,
Integrated Management of Childhood
Illness (IMCI).2 IMCI has since formed
the basis of child survival strategies
throughout the developing world. The
effectiveness of this approach is uncertain,
although it is clear that child mortality
has since fallen throughout most of the
developing world. Studies of the aetiology
of severe pneumonia have repeatedly
shown the dominant bacterial causes to be
Streptococcus pneumoniae (pneumococ-
cus) and Haemophilus inﬂuenzae (usually
type b or Hib), and these are generally
assumed to be responsible for most
deaths.
In a global public health effort that is
unprecedented since the UNICEF-WHO
led Universal Childhood Immunisation
campaign of the 1980s, the international
community is in the process of rolling out
new expensive vaccines, including Hib
and pneumococcal conjugate vaccines
(PCVs) into the poorest countries of the
world (http://www.gavi.org/support/nvs/
pneumococcal/).3 This is not just the latest
in a series of new vaccines to be added to
national programmes. Hib and PCV intro-
duction represent a direct attack on the
leading cause of child illness and death in
the world today, pneumonia. Yet curiously
the true burden of pneumonia, at national
and global levels, remains unclear. This is
in part because we lack clear deﬁnitions.
As most deaths from pneumonia occur
outside the health system in settings that
lack appropriate healthcare, pneumonia
mortality estimates are based on verbal
autopsy studies, in which the families of
deceased children are visited some
months after the death and their recollec-
tion of the course of the child’s ﬁnal
illness is recorded and interpreted by a
panel of doctors to identify the most
likely cause. This is of course very crude,
as are the models that are derived from
such studies combined with vital registra-
tion data. The result is a very wide range
of possible estimates for pneumonia mor-
tality.4 In recent years there have been a
series of global and regional estimates of
pneumonia mortality by speciﬁc aetiology,
also using models that are based on very
sparse data. In fact the only valid
approach to understanding pneumonia
burden by aetiology comes from vaccine
trials designed to measure the impact of
Hib and pneumococcal vaccines.5 These
trials used the WHO standard of radio-
graphic pneumonia, and all found that the
radiological deﬁnition was the pneumonia
deﬁnition that produced the clearest dif-
ference between vaccinated and unvaccin-
ated children.6 By implication this was the
pneumonia deﬁnition that was most
enriched for bacterial pneumonia. This
has been used to provide an estimate of
the fraction of radiological pneumonia
cases due to the immunisation target (Hib
or pneumococcus), and this is used, in
turn to estimate the distribution of pneu-
monia deaths by bacterial aetiology.7 8
When it comes to understanding the
morbidity burden of pneumonia we are
not in much better shape. There have
been brave efforts to develop global con-
clusions based on meta-analysis of many
studies that used a variety of surveillance
methods and deﬁnitions. These have
attempted to apply WHO IMCI deﬁni-
tions to the various studies, and
concluded that, in developing countries,
the overall incidences of pneumonia and
severe pneumonia are 290 and 19.7 per
1000 child-years, respectively, for children
under 5 years of age.9 10 In fact, prospect-
ive studies of the burden of pneumonia
are rare, and again the best data available
come from trials of Hib or pneumococcal
vaccines. In rural Gambia the incidences
of pneumonia and severe pneumonia in
children 6 weeks–2 years were 249 and
15 per 1000 child-years, respectively, in a
pneumococcal vaccine trial.5 Two recent
studies from South Africa address the
childhood pneumonia burden from two
perspectives. Madhi et al, writing in this
journal, present a case control study of
the impact of PCV introduction on pneu-
monia in South Africa, while in another
publication, le Roux et al11 present a fas-
cinating look at pneumonia in two rather
different communities after the introduc-
tion of PCVs in South Africa.
The Madhi study uses a case control
methodology to evaluate the impact of
PCVs on pneumonia in South Africa. To
deﬁne pneumonia they used the WHO
radiological deﬁnition, but added a softer
group with non-speciﬁc X-ray changes
and an elevated C-reactive protein (CRP).
This probably did not affect the results as
only 22% ﬁtted into this category. The
use of case control methodology to evalu-
ate vaccine effectiveness is based on the
comparison of vaccination rates among
cases and controls of the same age. A rela-
tively simple formula is used to calculate
vaccine effectiveness from ORs. However
the approach has some problems that are
evident in this study. The ﬁrst is the
choice of controls. The control group is
used as a measure of the vaccine coverage
in the community, against which the vac-
cination statuses of cases are compared. In
short, a lower rate of vaccination among
cases can be translated into a measure of
vaccine effectiveness. Identifying and sam-
pling the community from which the
cases are drawn is not easy, especially in
settings where access to care varies within
a community. The choice is between con-
trols recruited from hospitalised patients
potentially matched for known confoun-
ders, and community controls, recruited
from neighbouring households, or (better)
selected randomly from a community
database, as was done in the Madhi study.
Whether hospital or community controls
are used there is always a problem with
refusals. Potential controls who refuse are
less likely to be vaccinated, so the more
refusals there are the greater the estimate
of vaccine coverage in the community,
and the greater the measured
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effectiveness. In this study we are not
given information about refusals.
Hospital-based controls on the other
hand, are ill and may not be representa-
tive of the population from which the
cases have been drawn. It is also possible
that their hospitalisation is associated with
risk factors of interest, which may lead to
biased estimates of vaccine effectiveness.
In the Madhi study, the authors address
the challenges of selecting suitable con-
trols by recruiting two different control
groups; age-matched hospital controls
were recruited for all sites, and for
Soweto community controls were also
recruited. The results are presented as
crude estimates (taking no account for
confounding factors) and adjusted esti-
mates (controlled for potential confound-
ing variables). In the case of rare diseases,
such as meningitis, where the dominant
risk factors can be seen as lack of immun-
isation and bad luck, this can be expected
to produce reliable results. This may not
be the case with pneumonia, as risk of
pneumonia is largely due to factors such
as malnutrition, poverty and crowding,
and it can be expected that higher-risk
children may be less likely to be immu-
nised, leading to an elevation in measured
effectiveness.
In fact what we see with this study is a
wide range of estimates with effectiveness
estimates derived from use of community
controls declining when risk factors are
adjusted for, as we might expect, but with
the analysis of hospital controls the
opposite trend occurs, which is hard to
understand. From these results we can
conclude that PCV introduction seems to
be associated with a reduction in radio-
logical pneumonia incidence among
HIV-negative South African children, but
we cannot quantify the effect.
Our understanding of the burden and
trends of childhood pneumonia has been
greatly limited by unclear deﬁnitions, and
a startling lack of research. The situation
has been complicated by the recent deci-
sion by WHO to alter the deﬁnition of
‘severe pneumonia requiring admission’.
Until 2013, the deﬁnition was based on
the presence of lower chest wall indrawing
or danger signs. Since 2013 lower chest
wall indrawing has been dropped from
the deﬁnition, while other signs such as
respiratory distress have been added.
The changes in the WHO deﬁnitions of
severe pneumonia span the enrolment
period for the recent prospective study of
pneumonia epidemiology by le Roux et al
(May 2012–May 2014).11 It is important
to note that the study was conducted after
the introduction of the 13-valent PCV in
South Africa in 2011. The analysis of the
study incorporates the new WHO deﬁn-
ition. The incidence rates of pneumonia
and severe pneumonia in the study were
270 and 60 per 100 000 child-years,
respectively. The high rate of severe pneu-
monia is based on only 32 cases and may
reﬂect some uncertainty with the chan-
ging deﬁnitions. The continuing high rate
of clinical pneumonia may appear to indi-
cate that the vaccine has had little impact,
but this may also reﬂect the fairly intense
monitoring of the cohort.
The contrasting nature of the two com-
munities involved in the study make the le
Roux study a truly fascinating and import-
ant study. While in Mbekweni, the pre-
dominantly black African community is
poorer and less likely to be living in
formal housing, with a higher prevalence
of maternal HIV infection, their children
have a lower incidence of pneumonia than
those of the predominantly mixed-race
TC Newman community (220 vs 320 epi-
sodes per 1000 child-years). This appears
to be related to three important risk
factors:
1. Maternal smoking, which was much
higher in the TC Newman community
2. Nutrition, which was substantially
worse in the TC Newman community,
and
3. Crowding, which was also worse in
the TC Newman community, despite
the factors mentioned above
The nutrition differences are of interest.
While more Mbekweni children were
never breastfed, possibly due to the
HIV-positive mothers being advised not
to breastfeed, birth weights were lower in
the TC Newman community, presumably
due to maternal smoking. Rates of exclu-
sive breastfeeding were low and similar in
both communities, but it seems possible
that qualitative aspects of breastfeeding
were superior in the Mbekweni commu-
nity. Overall the study highlights the dev-
astating impact of maternal smoking on
the respiratory health of children, prob-
ably overwhelming all other risk factors.
This study was undertaken in a commu-
nity with good vaccination coverage.
Seventy per cent of children received the
primary series of three doses of Hib and
two doses of PCV, with most receiving the
third dose of pneumococcal vaccine at or
soon after 9 months. Those vaccines, and
probably other trends associated with
development and availability of antibio-
tics, are changing global patterns of
pneumonia epidemiology while the inter-
national community continues not to
monitor these effects in any systematic
way. In the present study mortality was
low; only one child actually died of pneu-
monia. Meanwhile the prevalence of
wheezing was high, with over 60% of
pneumonia cases having wheeze. This is
becoming a common feature of pneumo-
nia studies in some parts of the world,
especially south Asia. This raises difﬁcul-
ties in interpretation, and is closely related
to the WHO decision to change the deﬁn-
ition of severe pneumonia. Lower chest
wall indrawing has been a strong sign of
severe pneumonia and a recent study of
factors identiﬁed with a fatal outcome in
pneumonia found indrawing to be an
important sign.12 It is also a common sign
in wheezing children, especially infants in
whom the likely diagnosis is bronchio-
litis.13 Growing dissatisfaction with this
component of the WHO deﬁnitions is
likely to be associated with an increasing
proportion of children classiﬁed as severe
pneumonia who actually have wheezing
illness, with a much lower probability of a
fatal outcome. This led to a series of
studies of community management of
severe pneumonia, which generally
showed this approach to be safe and
effective. Many children in those studies
had wheezing and case fatality rates were
extremely low, raising serious doubts
about the applicability of the study results
to high mortality settings where wheezing
is not so common.14
Here again the international commu-
nity is shamed by its lack of serious pro-
spective studies of respiratory disease in
children in a range of settings. With
notable exceptions of internationally
funded studies of particular communities,
such as those in Mozambique, Gambia,
Kenya, Vietnam and Bangladesh, there are
few studies monitoring communities at a
time when the epidemiology is changing,
under the inﬂuence of speciﬁc measures
such as new vaccines as well as rapid soci-
etal changes such as urbanisation. We
must ﬁrst recognise those studies that
publish data that are partly or totally
modelled. Then studies such as the study
of le Roux et al must be supported and
converted to long-term cohort studies.
Understanding the overall impact of
vaccines on pneumonia is not a simple
task. The case control methodology seems
like the logical way to approach this, but
the Madhi study shows just how difﬁcult
this approach is, and how uncertain the
results may be. Of particular concern is
the susceptibility to bias with this
approach. A recently completed multi-
country study of the aetiology of child-
hood pneumonia, the Pneumonia
Etiology Research for Child Health
(PERCH) study, has attempted to deﬁne
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the aetiological causes of pneumonia in
settings of new vaccine introduction.
While the long awaited publication of
PERCH data may provide some indication
of how pneumonia aetiology has changed
since the last such study, over 20 years
ago, it seems likely that the variable preva-
lence of wheeze in the sites will limit that
interpretation. What is needed now are
more long-term prospective studies under-
taken in settings where community devel-
opment, healthcare and public health
interventions are evolving. Such studies
need to use common methodologies to
address trends in the incidence of pneu-
monia, the prevalence of wheezing and
pneumonia mortality rates. Only then can
we begin to understand the changes in the
patterns of respiratory diseases that ﬁll the
paediatric wards of developing countries,
still kill many children, and lay the foun-
dation for an unknown burden of chronic
respiratory disease in tomorrow’s adults.
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